EP1646644A2 - Proteines d'interaction posh et procedes connexes - Google Patents

Proteines d'interaction posh et procedes connexes

Info

Publication number
EP1646644A2
EP1646644A2 EP04716503A EP04716503A EP1646644A2 EP 1646644 A2 EP1646644 A2 EP 1646644A2 EP 04716503 A EP04716503 A EP 04716503A EP 04716503 A EP04716503 A EP 04716503A EP 1646644 A2 EP1646644 A2 EP 1646644A2
Authority
EP
European Patent Office
Prior art keywords
posh
agent
polypeptide
protein
inhibits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04716503A
Other languages
German (de)
English (en)
Other versions
EP1646644A4 (fr
Inventor
Daniel N. Taglicht
Iris Alroy
Yuval Reiss
Liora Yaar
Danny Ben-Avraham
Shmuel Tuvia
Tsvika Greener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteologics Inc
Original Assignee
Proteologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/035712 external-priority patent/WO2004098492A2/fr
Priority claimed from PCT/US2004/003600 external-priority patent/WO2004073609A2/fr
Application filed by Proteologics Inc filed Critical Proteologics Inc
Publication of EP1646644A2 publication Critical patent/EP1646644A2/fr
Publication of EP1646644A4 publication Critical patent/EP1646644A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

L'invention porte sur de nouveaux complexes de polypeptides POSH et sur des protéines associées à POSH, ainsi que sur des procédés et sur des compositions permettant de traiter des maladies associées à POSH telles que des maladies virales, le cancer et des troubles neurologiques.
EP04716503A 2003-03-03 2004-03-02 Proteines d'interaction posh et procedes connexes Withdrawn EP1646644A4 (fr)

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US45143703P 2003-03-03 2003-03-03
US45228403P 2003-03-05 2003-03-05
US45576003P 2003-03-19 2003-03-19
US45664003P 2003-03-20 2003-03-20
US46052603P 2003-04-03 2003-04-03
US46079203P 2003-04-04 2003-04-04
US46428503P 2003-04-21 2003-04-21
US46946203P 2003-05-09 2003-05-09
US47137803P 2003-05-15 2003-05-15
US47232703P 2003-05-20 2003-05-20
US47470603P 2003-05-30 2003-05-30
US47582503P 2003-06-03 2003-06-03
US47931703P 2003-06-17 2003-06-17
US48037603P 2003-06-19 2003-06-19
US48021503P 2003-06-19 2003-06-19
US49386003P 2003-08-08 2003-08-08
US49863403P 2003-08-28 2003-08-28
US50393103P 2003-09-16 2003-09-16
PCT/US2003/035712 WO2004098492A2 (fr) 2002-11-11 2003-11-10 Processus associes au reseau trans-golgi et methodes et compositions associees
PCT/US2004/003600 WO2004073609A2 (fr) 2003-02-05 2004-02-05 Kinases associees a posh et methodes correspondantes
US54989604P 2004-03-02 2004-03-02
PCT/US2004/006308 WO2004078130A2 (fr) 2003-03-03 2004-03-02 Proteines d'interaction posh et procedes connexes

Publications (2)

Publication Number Publication Date
EP1646644A2 true EP1646644A2 (fr) 2006-04-19
EP1646644A4 EP1646644A4 (fr) 2007-05-16

Family

ID=36091550

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04716503A Withdrawn EP1646644A4 (fr) 2003-03-03 2004-03-02 Proteines d'interaction posh et procedes connexes

Country Status (4)

Country Link
EP (1) EP1646644A4 (fr)
AU (1) AU2004218430A1 (fr)
CA (1) CA2517525A1 (fr)
WO (1) WO2004078130A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE458485T1 (de) * 2003-07-11 2010-03-15 Proteologics Inc Ubiquitin-ligase-hemmer und verwandte verfahren
US20060188890A1 (en) * 2003-10-31 2006-08-24 Proteologics, Inc. Ubiquitin-based protein interaction assays and related compositions
AT506041A1 (de) 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
WO2011062962A2 (fr) * 2009-11-17 2011-05-26 The Trustees Of The University Of Pennsylvania Dégron smndelta7 : nouvelles compositions et procédés d'utilisation
EP2471548A1 (fr) 2010-12-28 2012-07-04 Apeiron Biologics AG siRNA contre la Cbl-b et optionnellement l'IL2 et l'IL12 pour l'utilisation dans le traitement du cancer
JP6628226B2 (ja) * 2014-01-17 2020-01-08 洋孝 松尾 痛風発症素因の評価方法
US11286489B2 (en) * 2016-02-11 2022-03-29 The Curators Of The University Of Missouri POSH inhibitor complex biomolecules and amphiphile micelles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089302A2 (fr) * 2003-04-03 2004-10-21 Proteologics, Inc. Polypeptides posh, complexes et procedes correspondants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004089302A2 (fr) * 2003-04-03 2004-10-21 Proteologics, Inc. Polypeptides posh, complexes et procedes correspondants

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ACHTERBERG VAN T A: "POSH 4,A NOVEL PUTATIVE TRANSCRIPTION FACTOR, INTERACTS WITH A SPECIFIC HUMAN SPROUTY 4 ISOFORM" BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 98, no. 11, PART 1, 16 November 2001 (2001-11-16), page 823A, XP001079229 ISSN: 0006-4971 *
ETTENBERG SETH A ET AL: "Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 29, 20 July 2001 (2001-07-20), pages 27677-27684, XP002376201 ISSN: 0021-9258 *
JISHAGE M ET AL: "IDENTIFICATION OF TARGET GENES FOR EWS/ATF-1 CHIMERIC TRANSCRIPTION FACTOR" ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 22, no. 1, 9 January 2003 (2003-01-09), pages 41-49, XP001152880 ISSN: 0950-9232 *
KEANE MACCON M ET AL: "cbl-3: A new mammalian cbl family protein" ONCOGENE, vol. 18, no. 22, 3 June 1999 (1999-06-03), pages 3365-3375, XP002376200 ISSN: 0950-9232 *
KOKAME K ET AL: "HERP, A NEW UBIQUITIN-LIKE MEMBRANCE PROTEIN INDUCED BY ENDOPLASMIC RETICULUM STRESS" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 275, no. 42, 20 October 2000 (2000-10-20), pages 32846-32853, XP002951095 ISSN: 0021-9258 *
MCKENNA S ET AL: "Energetics and specificity of interactions within Ub Uev Ubc13 human ubiquitin conjugation complexes" BIOCHEMISTRY 08 JUL 2003 UNITED STATES, vol. 42, no. 26, 8 July 2003 (2003-07-08), pages 7922-7930, XP002426501 ISSN: 0006-2960 *
SAI X ET AL: "Endoplasmic reticulum stress-inducible protein, Herp, enhances presenilin-mediated generation of amyloid [beta]-protein" JOURNAL OF BIOLOGICAL CHEMISTRY 12 APR 2002 UNITED STATES, vol. 277, no. 15, 12 April 2002 (2002-04-12), pages 12915-12920, XP002426500 ISSN: 0021-9258 *
See also references of WO2004078130A2 *
SMIT L ET AL: "The Cbl family of signal transduction molecules" CRITICAL REVIEWS IN ONCOGENESIS 1997 UNITED STATES, vol. 8, no. 4, 1997, pages 359-379, XP009064975 ISSN: 0893-9675 *
ULRICH H D: "Protein-protein interactions within an E2-RING finger complex: Implications for ubiquitin-dependent DNA damage repair" JOURNAL OF BIOLOGICAL CHEMISTRY 28 FEB 2003 UNITED STATES, vol. 278, no. 9, 28 February 2003 (2003-02-28), pages 7051-7058, XP002426502 ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2004078130A2 (fr) 2004-09-16
WO2004078130A3 (fr) 2006-01-12
AU2004218430A1 (en) 2004-09-16
EP1646644A4 (fr) 2007-05-16
CA2517525A1 (fr) 2004-09-16

Similar Documents

Publication Publication Date Title
US20050214751A1 (en) Inhibition of viral maturation, methods and compositions related thereto
US20070054355A1 (en) Cbl-b polypeptides, complexes and related methods
US7429643B2 (en) POSH nucleic acids, polypeptides and related methods
US20130131094A1 (en) Pyrimidine derivatives as posh and posh-ap inhibitors
Velasco et al. An N-terminal SIAH-interacting motif regulates the stability of the ubiquitin specific protease (USP)-19
WO2004078130A2 (fr) Proteines d'interaction posh et procedes connexes
US20060287337A1 (en) Trans-golgi network-associated processes, methods and compositions related thereto
US20070122807A1 (en) Posh polypeptides, complexes and related methods
US20060286630A1 (en) Posh interacting proteins and related methods
US20070275368A1 (en) Posh Associated Kinases And Related Methods
WO2004098492A2 (fr) Processus associes au reseau trans-golgi et methodes et compositions associees
US20070060537A1 (en) Methods and compositions for inhibiting viral infections
US20070141716A1 (en) Pem-3-like compositions and related methods thereof
WO2003060067A2 (fr) Acides nucleiques et polypeptides p85-alpha, et procedes associes
WO2005038007A2 (fr) Posh et proteines associees
WO2007088531A2 (fr) Polypeptides pem-3-like, complexes et procédés associés
US20120015967A1 (en) Pyrimidine and pyridine derivatives as posh and posh-ap inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050929

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 21/00 20060101ALI20060419BHEP

Ipc: C12N 15/00 20060101ALI20060419BHEP

Ipc: C12N 9/00 20060101ALI20060419BHEP

Ipc: C07K 14/00 20060101AFI20060419BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/435 20060101ALI20060904BHEP

Ipc: A61P 31/14 20060101ALI20060904BHEP

Ipc: A61P 31/12 20060101ALI20060904BHEP

Ipc: A61K 31/341 20060101ALI20060904BHEP

Ipc: A61K 31/427 20060101ALI20060904BHEP

Ipc: A61K 31/428 20060101ALI20060904BHEP

Ipc: A61K 31/426 20060101ALI20060904BHEP

Ipc: A61K 31/4015 20060101ALI20060904BHEP

Ipc: A61K 31/515 20060101AFI20060904BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GREENER, TSVIKA

Inventor name: TUVIA, SHMUEL

Inventor name: BEN-AVRAHAM, DANNY

Inventor name: YAAR, LIORA

Inventor name: REISS, YUVAL

Inventor name: ALROY, IRIS

Inventor name: TAGLICHT, DANIEL, N.

A4 Supplementary search report drawn up and despatched

Effective date: 20070418

17Q First examination report despatched

Effective date: 20070806

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080217